Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA

Cancer Gene Therapy

Volumn 11, Issue 8, 2004, Pages 539-546

  Ferrer, Miriam ^a   De Winter, Johan P ^a   Mastenbroek, D C Jeroen ^a   Curiel, David T ^b   Gerritsen, Winald R ^a   Giaccone, Giuseppe ^a   Kruyt, Frank A E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Chemotherapy; Fanconi anemia; NSCLC; Resistance

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; GENE PRODUCT; PROTEIN; PROTEIN FANCA600DN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOMINANT GENE; DRUG SENSITIVITY; DRUG TARGETING; EMBRYO; FANCONI ANEMIA; FEMALE; GENE DISRUPTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPHOBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCID MOUSE; TUMOR GROWTH; UBIQUITINATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL EXTRACTS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP G PROTEIN; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOPRECIPITATION; MICE; NEOPLASMS; NUCLEAR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 4043083351     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700734     Document Type: Article

References (33)

1. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1:130-141.
2. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:763-771.
3. Rosenberg E, Taher MM, Kuemmerle NB, Farnsworth J, Valerie K. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res. 2001;61:764-770.
4. Fanconi G. Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). I. Clinical aspects. Semin Hematol. 1967;4:233-240.
5. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-457.
6. Ishida R, Buchwald M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res. 1982;42:4000-4006.
7. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-396.
8. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for two new genetic subtypes. Blood. 2004;103:2498-2503.
9. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34.
10. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35:165-170.
11. Positional cloning of the Fanconi Anaemia Group A Gene. The Fanconi anaemia/breast cancer consortium. Nat Genet. 1996;14:324-328.
12. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet. 1996;14:320-323.
13. de Winter JP, van der Woel L, de Groot J, et al. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet. 2000;9:2665-2674.
14. Medhurst AL, Huber PA, Waisfisz Q, de Winter JP, Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum Mol Genet. 2001;10:423-429.
15. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell. 2001;7:241-248.
16. Bogliolo M, Cabre O, Callen E, et al. The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis. 2002;17:529-538.
17. Grompe M, D'Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet. 2001;10:2253-2259.
18. Gregory RC, Taniguchi T, D'Andrea AD. Regulation of the Fanconi anemia pathway by monoubiquitination. Semin Cancer Biol. 2003;13:77-82.
19. Siddique MA, Nakanishi K, Taniguchi T, Grompe M, D'Andrea AD. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Exp Hematol. 2001;29:1448-1455.
20. Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H. Resistance to mitomycin C requires direct interaction between the Fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain. J Biol Chem. 1999;274:34212-34218.
21. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
22. van Beusechem VW, van Rijswijk AL, van Es HH, et al. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Therapy. 2000;7:1940-1946.
23. Carreau M, Alon N, Bosnoyan-Collins L, Joenje H, Buchwald M. Drug sensitivity spectra in Fanconi anemia lymphoblastoid cell lines of defined complementation groups. Mutat Res. 1999;435:103-109.
24. Garcia-Higuera I, Kuang Y, Denham J, D'Andrea AD. The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. Blood. 2000;96:3224-3230.
25. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy. 2001;8:1347-1353.
26. Yu Q, Que LG, Rockey DC. Adenovirus-mediated gene transfer to nonparenchymal cells in normal and injured liver. Am J Physiol Gastrointest Liver Physiol. 2002;282:G565-G572.
27. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568-574.
28. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7:249-262.
29. Folias A, Matkovic M, Bruun D, et al. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum Mol Genet. 2002;11:2591-2597.
30. Taniguchi T, Garcia-Higuera I, Andreassen PR, et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 2002;100:2414-2420.
31. Joenje H, Arwert F. Connecting Fanconi anemia to BRCA1. Nat Med. 2001;7:406-407.
32. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
33. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther. 2002;13:485-495.